Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats

Authors:

Abstract
Fluoroquinolone use in children is limited due to its potential toxicity and negative effects on skeletal development, but the actual effects/risks of fluoroquinolones on bone growth and the mechanisms behind fluoroquinolone-driven arthropathy remain unknown. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic with a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones.
Funding Information
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)
  • GSK (Study number I12099)

This publication has 35 references indexed in Scilit: